Brenna C. Carey, MS, PhD
- Member, Translational Pulmonary Center
- Member, Division of Pulmonary Biology
- Assistant Professor, UC Department of Pediatrics
About
MS: Pharmaceutical Sciences with Specialization in Drug Development, University of Cincinnati, College of Pharmacy, Cincinnati, OH, 2010
PhD: Molecular and Developmental Biology, University of Cincinnati, College of Medicine, Cincinnati, OH, 2003
BS: Biology, John Carroll University, University Heights, OH, 1998
Post-doctoral Research Fellow: Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2008
Interests
Regulations, management, and coordination of clinical research trials in rare lung diseases, specifically pulmonary alveolar proteinosis (PAP); pathogenesis of PAP; developing and validating clinical research tests to diagnose PAP; evaluating several therapeutic options for individuals with PAP; translational pulmonary science; rare lung disease clinical research diagnostic testing; diagnosis of individuals with hereditary or autoimmune PAP clinical trials; National PAP Registry; inhaled GM-CSF treatment for individuals with autoimmune PAP and hereditary PAP; safety and efficacy of Pioglitazone for autoimmune PAP patients
Research Areas
Publications
B28-23 Gm-csf Signaling Deficiency Causes Marked Pulmonary Lymphocytosis Due to Alveolar Macrophage-mediated Recruitment, Altered Lymphoid-myeloid Lineage Commitment, and Local Proliferation. American Journal of Respiratory and Critical Care Medicine. 2026; 212(Supplement_1):aamag162.1143.
B76-04 Alpha-1 Knockout Mice Have Increased Lung Inflammatory Cytokines That Correlate With Protease Activities. American Journal of Respiratory and Critical Care Medicine. 2026; 212(Supplement_1):aamag162.1856.
C39-09 A Practical Tool for Measuring the Severity of Lung Disease in Pulmonary Alveolar Proteinosis. American Journal of Respiratory and Critical Care Medicine. 2026; 212(Supplement_1):aamag162.2658.
C104-15 Diagnosis and Treatment of Autoimmune Pulmonary Alveolar Proteinosis: Results From the US National PAP Registry. American Journal of Respiratory and Critical Care Medicine. 2026; 212(Supplement_1):aamag162.2829.
DEVELOPMENT OF A DRIED SERUM ASSAY FOR THE DETECTION OF GM-CSF ANTIBODIES TO AID IN THE DIAGNOSIS OF AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP) Chest. 2025; 168(4):a3757.
Pharmacokinetics and pharmacodynamics of inhaled molgramostim in healthy people. BMJ Open Respiratory Research. 2025; 12(1).
Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis. New England Journal of Medicine. 2025; 393(8):764-773.
Autoimmune Pulmonary Alveolar Proteinosis: Update from the US National PAP Registry. American Journal of Respiratory and Critical Care Medicine. 2025; 211(Supplement_1):a1814-a1814.
Pulmonary hypertension during high-dose GM-CSF therapy of autoimmune pulmonary alveolar proteinosis. Pulmonary Circulation. 2024; 14(4):e70020.
A toxicology study of Csf2ra complementation and pulmonary macrophage transplantation therapy of hereditary PAP in mice. Molecular Therapy: Methods & Clinical Development. 2024; 32(2):101213.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 2026 Cincinnati Children's Hospital Medical Center. All rights reserved.
